{
    "root": "93e680bc-fd2e-4df7-9c72-70695026ad8d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZYMFENTRA",
    "value": "20250528",
    "ingredients": [
        {
            "name": "INFLIXIMAB-DYYB",
            "code": "B72HH48FLU"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        }
    ],
    "indications": "zymfentra tumor necrosis factor ( tnf ) blocker indicated adults maintenance treatment : moderately severely active ulcerative colitis following treatment infliximab product administered intravenously . ( 1 ) moderately severely active crohn ’ disease following infliximab products administered intraneously . ( 1 )",
    "contraindications": "important information . ( 2.1 ) . zymfentra indicated maintenance treatment , starting week 10 thereafter . ▫ pateitns must complete intravenous induction regiemen infliximab product starting zymfentra . zymfentra subcutaneous . recommeneded maintenance ulcerative colitis crohn 's direase ( 2.2 ) week 10 thereafter : inject 120 mg subcutaneously every two weeks . swift patients responding maintenance therapy infliximab product administered intravenously , administer first subcutaneous dose zymfentra place next scheduled intravenous infusion every two weeks thereafter . full prescribing information administer subcutaneously . ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "zymfentra contraindicated patients history severe hypersensitivity reaction infliximab-dyyb , infliximab products , inactive ingredients zymfentra , murine proteins . included anaphylaxis [ ( 5.7 ) ] .",
    "indications_original": "ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following with an infliximab products administered intraneously. ( 1 )",
    "contraindications_original": "Important Dosage Information. ( 2.1 ). ZYMFENTRA is indicated as maintenance treatment only, starting at Week 10 and thereafter. ▫ All pateitns must complete an intravenous induction regiemen with an infliximab product before starting ZYMFENTRA. ZYMFENTRA is for subcutaneous use only. Recommeneded Maintenance Dosage in Ulcerative Colitis and Crohn's Direase ( 2.2 ) Week 10 and thereafter : Inject 120 mg subcutaneously once every two weeks. To swift patients who are responding to maintenance therapy with an infliximab product administered intravenously, administer the first subcutaneous dose of ZYMFENTRA in place of the next scheduled intravenous infusion and every two weeks thereafter. See the full prescribing information on how to administer subcutaneously. ( 2.3 )",
    "adverseReactions_original": "ZYMFENTRA is contraindicated in patients with a history of a severe hypersensitivity reaction to infliximab-dyyb, other infliximab products, any of the inactive ingredients in ZYMFENTRA, or any murine proteins. Reactions have included anaphylaxis [see Warnings and Precautions (5.7)]."
}